Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2012-09-23 Annual Report
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Open Briefing 4 pages 312.9KB
Annual Report Classification · 95% confidence The document is an 'Open Briefing' interview with the CEO and MD discussing the company's full fiscal year 2012 results and outlook for 2013. It includes detailed discussion of financial performance (net cash outflow, R&D expenditure, royalty income), strategic plans, clinical development updates, and funding status. The content is substantive and covers a full fiscal year, indicating it is a comprehensive financial and operational report rather than a brief announcement or presentation. There is no indication that this is a transcript of a call, a regulatory filing, or a simple announcement of a report. The document length (over 11,000 characters) and detailed financial and strategic content align with an Annual Report or equivalent comprehensive yearly report. Given the Australian context and the fiscal year reference (FY2012), this aligns with the Annual Report category (10-K equivalent). Therefore, the document is best classified as an Annual Report (10-K). FY 2012
2012-09-23 English
Notice under section 708A(5)(e) of the Corporations Act 2001 1
Share Issue/Capital Change Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of securities (ordinary shares) by Circadian Technologies Limited. It details the class, ASX code, date, and total number of securities issued. The document is a formal announcement of a share issue without disclosure under certain provisions of the Corporations Act. It does not contain financial statements, management discussion, or detailed financial data. The document is short (1542 characters) and serves as a regulatory announcement about a capital event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2012-08-23 English
Appendix 3B 7 pages 126.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, and application for quotation of additional securities on the ASX. It is a formal announcement related to capital raising and securities issuance rather than a financial report or earnings release. The document is consistent with a capital/financing update filing, specifically announcing new share issuance and related details. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-08-23 English
Preliminary Final Report 95 pages 1.4MB
Annual Report Classification · 100% confidence The document is titled 'PRELIMINARY FINAL REPORT (APPENDIX 4E) FINANCIAL YEAR ENDED 30 JUNE 2012' and includes detailed financial results, directors' report, operations report, auditor's independence declaration, financial statements, directors' declaration, and independent auditor's report. It covers the full financial year ended 30 June 2012, indicating it is a comprehensive annual financial report. The presence of detailed financial statements and analysis confirms it is not merely an announcement or summary. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are annual reports. Therefore, this document fits the definition of an Annual Report (10-K equivalent). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement of its publication. FY 2012
2012-08-22 English
Change in substantial holding for ANP 5 pages 44.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 "Notice of Change of Interests of Substantial Holder" filed under the Corporations Act 2001. It details changes in substantial shareholdings of Polychip Pharmaceuticals Pty Ltd and Syngene Limited in Antisense Therapeutics Limited, including voting power percentages and share transactions. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category 'Major Shareholding Notification' (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes. Therefore, the correct classification is MRQ with high confidence.
2012-07-16 English
Appendix 3Y 3 pages 39.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the change, the nature of the transaction (on-market trade), and the value of consideration. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management commentary. Therefore, it fits the definition of 'Director's Dealing' (DIRS). The document length is under 5,000 characters and is not an announcement of a report but the actual notice of director's interest change.
2012-07-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.